Case Report
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
Table 2
Reported cases of docetaxel-induced SJS.
| Author | Year | Type of article | Description of case/study | Outcome |
| Moisidis and Möbus [1] | 2005 | Case report | 76-year-old female with metastatic breast cancer with docetaxel-induced erythema multiforme | Resolution of symptoms after 3 weeks following treatment with high-dose steroids | Dourakis et al. [5] | 2002 | Case report | 60-year-old patient with non-Hodgkin’s lymphoma and received salvage therapy with docetaxel and prednisone developed SJS within 5 days of treatment | Received treatment with supportive measures and survived | Arshad et al. [6] | 2014 | Case report | 46-year-old female with metastatic breast cancer developed SJS two weeks following treatment with three cycles of docetaxel. | She was supportively managed. | Sawada et al. [7] | 2009 | Case report | 56-year-old female treated for metastatic breast cancer with first cycle of docetaxel developed SJS. | She received treatment with topical clobetasol and triamcinolone and other supportive measures. The patient survived with resolution of symptoms. | Ohlmann et al. [8] | 2007 | Case report | 67-year-old male with prostate cancer received docetaxel as a part of a randomized phase III trial developed SJS after five cycles of treatment. | Patient received systemic steroids and antibiotics for treatment and succumbed as a result of SJS secondary to docetaxel. | Kattan et al. [9] | 2008 | Clinical trial, open-labelled phase II | 27 patients received weekly docetaxel and zoledronic acid and estramustine between 2002 and 2014 for hormone refractory prostate cancer. | 1 patient died of docetaxel toxicity in the form of SJS, 2 weeks after the second cycle. |
|
|